INJOURNEY Trial Data Shows Ofev-Esbriet Combo Is Safe and IPF Patients Tolerate It Well
Idiopathic Pulmonary Fibrosis, News
A combination of Boehringer Ingelheim‘s Ofev (nintedanib) and Genentech’s Esbriet (pirfenidone) as a treatment for idiopathic pulmonary fibrosis (IPF) was safe and well tolerated, according to the latest data from the Phase 4 INJOURNEY trial. ... Read more